Evaluating proposals
Innovative therapies for skin diseases
Maximising the value of your assets for patients suffering from a dermatological condition
Our Aim
We are looking for partnering opportunities on new assets (small molecules, biologics, or advanced therapies) in clinical or preclinical development stages that could be used for the treatment of dermatological conditions.
Preferably, the assets should target immuno-inflammatory pathways with rationale for dermatological indications, such as atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo, or be suitable for non-melanoma skin cancer, or rare dermatological indications.
Our interest
New assets in clinical or preclinical development stages
What we offer
Access to our expertise in dermatological R&D
Your benefit
A partnership opportunity
Shared goal
Finding innovative therapies for patients
Who is this for?
Universities
Biotechs
Public and private Research institutions
Start-ups
Pharmaceutical companies
For scientists at biotechs, start-ups, pharmaceutical companies, Universities, and eesearch institutions
Open from 20/07/22 to 04/11/22
Pharmacological profile of your asset & partnership opportunity
Collaborative framework
Submitted proposals may be eligible for a clinical or preclinical development partnership
You will retain ownership of any intellectual property you may bring or develop
Assets might be characterised on key dermatological in vitro and in vivo assays
A designated contact person will help answer your questions
Submitted proposals may be eligible for a clinical or preclinical development partnership
You will retain ownership of any intellectual property you may bring or develop
Assets might be characterised on key dermatological in vitro and in vivo assays
A designated contact person will help answer your questions
Collaboration process
Collaboration process
1
Proposal submission
From July 20th, 2022 to October 31st, 2022
2
Submissions will be handled following all applicable local compliance requirements
3
Proposal evaluation and selection
Within 4-8 weeks after submission
